Login to Your Account



Athersys shares gain ground on full-year stroke data

By Michael Fitzhugh
Staff Writer

Thursday, February 18, 2016

A year after treatment with Athersys Inc.'s Multistem cell therapy in a phase II trial, 23 percent of people who suffered an ischemic stroke achieved a clinically rated "excellent outcome" vs. just 8.2 percent of patients who received placebo.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription